Jennifer E. Kyle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jennifer E. Kyle has a total of 600 co-authors. Here are the top co-authors by number of shared publications:
- Ernesto Satoshi Nakayasu
Biological Sciences Division, Pacific Northwest National Laboratory
15 shared publications - Daniel S. Derrick
Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon
12 shared publications - Ferdinando Pucci
Ba Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA
12 shared publications - Jennifer M. Finan
Department of Surgery, Oregon Health & Science University, Portland, OR, USA
12 shared publications - Laura M. Heiser
Department of Biomedical Engineering, Oregon Health & Science University, Portland, USA
12 shared publications - Matthew Hoare
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK
12 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
A comprehensive proteogenomic, immunopeptidomic, and metabolomic atlas decodes immunogenicity in cutaneous melanoma
Cutaneous melanoma exhibits strong responses to immunotherapy, yet the system-level mechanisms linking mutational burden, genomic alterations, antigen landscapes, post-transcriptional and post-translational regulation, and immune outcomes remain incompletely defined. We profiled 183 cutaneous melanomas using 13 omic layers, including immunopeptidomics, metabolomics, protein ubiquitylation and glycosylation, to construct a holistic view of tumor immunogenicity. Mass spectrometry-based HLA-I immunopeptidomics revealed correlation between tumor antigens and CD8+ T-cell infiltration. Metabolomics revealed distinct ether-linked lipids and mitochondrial metabolic profiles between primary and metastatic tumors. Ubiquitylomics uncovered a subset of tumors associated with worse survival, characterized by high ubiquitylation of the IFN signaling pathway and ubiquitylation-dependent activation of AKT1. Glycoproteomic analyses identified GPNMB glycosylation as a key feature associated with sex-specific survival, linking this signal to a lysosome-associated program and suggesting potential sex-dependent differences in immunotherapy response. This multi-omic atlas of cutaneous melanoma illuminates mechanisms of immune evasion, informing treatment-relevant patient stratification in melanoma care.
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
Open AccessA comprehensive proteogenomic, immunopeptidomic, and metabolomic atlas decodes immunogenicity in cutaneous melanoma
Cutaneous melanoma exhibits strong responses to immunotherapy, yet the system-level mechanisms linking mutational burden, genomic alterations, antigen landscapes, post-transcriptional and post-translational regulation, and immune outcomes remain incompletely defined. We profiled 183 cutaneous melanomas using 13 omic layers, including immunopeptidomics, metabolomics, protein ubiquitylation and glycosylation, to construct a holistic view of tumor immunogenicity. Mass spectrometry-based HLA-I immunopeptidomics revealed correlation between tumor antigens and CD8+ T-cell infiltration. Metabolomics revealed distinct ether-linked lipids and mitochondrial metabolic profiles between primary and metastatic tumors. Ubiquitylomics uncovered a subset of tumors associated with worse survival, characterized by high ubiquitylation of the IFN signaling pathway and ubiquitylation-dependent activation of AKT1. Glycoproteomic analyses identified GPNMB glycosylation as a key feature associated with sex-specific survival, linking this signal to a lysosome-associated program and suggesting potential sex-dependent differences in immunotherapy response. This multi-omic atlas of cutaneous melanoma illuminates mechanisms of immune evasion, informing treatment-relevant patient stratification in melanoma care.
- Open Access
- 7 September 2026
- Published by Springer Nature in Communications Chemistry
Integrating data-dependent and data-independent acquisition methods for comprehensive lipidomic profiling using ion mobility spectrometry-mass spectrometry and a streamlined data analysis workflow
Lipidomics provides unique insights into the roles of lipids in cellular processes. In liquid chromatography tandem mass spectrometry-based lipidomics, data-dependent acquisition (DDA) provides cleaner spectra and supports higher confidence in lipid identification. Data-independent acquisition (DIA) allows more comprehensive characterization, but lipid identification is complicated by the highly multiplexed nature of MS/MS spectra without explicitly isolated precursor ions. In this work, we present an integrated workflow for comprehensive lipidomics analysis that incorporates both DDA (without ion mobility separation) and DIA (with ion mobility separation), leveraging the strengths of both acquisition methods. To streamline the data analysis, we developed a highly modular, Python-based data analysis workflow LipidIMEA . We applied this combined experimental and data analysis workflow to analyze complex lipid extracts from breast cancer patient-derived xenografts, evaluating the resulting lipid annotations for their coverage, confidence and repeatability.
- 7 September 2026
- Published by Springer Nature in Communications Chemistry
Open AccessIntegrating data-dependent and data-independent acquisition methods for comprehensive lipidomic profiling using ion mobility spectrometry-mass spectrometry and a streamlined data analysis workflow
Lipidomics provides unique insights into the roles of lipids in cellular processes. In liquid chromatography tandem mass spectrometry-based lipidomics, data-dependent acquisition (DDA) provides cleaner spectra and supports higher confidence in lipid identification. Data-independent acquisition (DIA) allows more comprehensive characterization, but lipid identification is complicated by the highly multiplexed nature of MS/MS spectra without explicitly isolated precursor ions. In this work, we present an integrated workflow for comprehensive lipidomics analysis that incorporates both DDA (without ion mobility separation) and DIA (with ion mobility separation), leveraging the strengths of both acquisition methods. To streamline the data analysis, we developed a highly modular, Python-based data analysis workflow LipidIMEA . We applied this combined experimental and data analysis workflow to analyze complex lipid extracts from breast cancer patient-derived xenografts, evaluating the resulting lipid annotations for their coverage, confidence and repeatability.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data and legends from Senescent Cell–Derived Extracellular Vesicles Inhibit Cancer Recurrence by Coordinating Immune Surveillance
Supplementary Data and legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data and legends from Senescent Cell–Derived Extracellular Vesicles Inhibit Cancer Recurrence by Coordinating Immune Surveillance
Supplementary Data and legends
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Senescent Cell–Derived Extracellular Vesicles Inhibit Cancer Recurrence by Coordinating Immune Surveillance
Senescence is a nonproliferative survival state that cancer cells can enter to escape therapy. In addition to soluble factors, senescence cells secrete extracellular vesicles (EV), which are important mediators of intercellular communication. To explore the role of senescent cell (SC)–derived EVs (senEV) in inflammatory responses to senescence, we developed an engraftment-based senescence model in wild-type mice and genetically blocked senEV release in vivo, without significantly affecting soluble mediators. SenEVs were both necessary and sufficient to trigger immune-mediated clearance of SCs, thereby suppressing tumor growth. In the absence of senEVs, the recruitment of MHC-II+ antigen-presenting cells (APC) to the senescence microenvironment was markedly impaired. Blocking senEV release redirected the primary target of SC signaling from APCs to neutrophils. Comprehensive transcriptional and proteomic analyses identified six ligands specific to senEVs, highlighting their role in promoting APC–T cell adhesion and synapse formation. APCs activated CCR2+CD4+ TH17 cells, which seemed to inhibit B-cell activation, and CD4+ T cells were essential for preventing tumor recurrence. These findings suggest that senEVs complement the activity of secreted inflammatory mediators by recruiting and activating distinct immune cell subsets, thereby enhancing the efficient clearance of SCs. These conclusions may have implications not only for tumor recurrence but also for understanding senescence during de novo carcinogenesis. Consequently, this work could inform the development of early detection strategies for cancer based on the biology of cellular senescence.Significance:Chemotherapy-treated senescent tumor cells release extracellular vesicles that trigger an immune response and suppress tumor recurrence.See related commentary by Almeida and Melo, p. 833
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Senescent Cell–Derived Extracellular Vesicles Inhibit Cancer Recurrence by Coordinating Immune Surveillance
Senescence is a nonproliferative survival state that cancer cells can enter to escape therapy. In addition to soluble factors, senescence cells secrete extracellular vesicles (EV), which are important mediators of intercellular communication. To explore the role of senescent cell (SC)–derived EVs (senEV) in inflammatory responses to senescence, we developed an engraftment-based senescence model in wild-type mice and genetically blocked senEV release in vivo, without significantly affecting soluble mediators. SenEVs were both necessary and sufficient to trigger immune-mediated clearance of SCs, thereby suppressing tumor growth. In the absence of senEVs, the recruitment of MHC-II+ antigen-presenting cells (APC) to the senescence microenvironment was markedly impaired. Blocking senEV release redirected the primary target of SC signaling from APCs to neutrophils. Comprehensive transcriptional and proteomic analyses identified six ligands specific to senEVs, highlighting their role in promoting APC–T cell adhesion and synapse formation. APCs activated CCR2+CD4+ TH17 cells, which seemed to inhibit B-cell activation, and CD4+ T cells were essential for preventing tumor recurrence. These findings suggest that senEVs complement the activity of secreted inflammatory mediators by recruiting and activating distinct immune cell subsets, thereby enhancing the efficient clearance of SCs. These conclusions may have implications not only for tumor recurrence but also for understanding senescence during de novo carcinogenesis. Consequently, this work could inform the development of early detection strategies for cancer based on the biology of cellular senescence.Significance:Chemotherapy-treated senescent tumor cells release extracellular vesicles that trigger an immune response and suppress tumor recurrence.See related commentary by Almeida and Melo, p. 833
- Open Access
- 4 May 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (3)
Assessing current capabilities for incorporating lipidomics in multiomics data integration
Comprehensive analyses of multiple biological components including nucleic acids, proteins, metabolites, and lipids (i.e. “multiomics”) provide unique insights into complex biological processes. Combining insights from these components through multiomics data integration enhances the depth and nuance of biological understanding available from these measurements. Among methods that integrate data across different technologies (e.g. mass spectrometry, sequencing), those that link components based on biological prior knowledge—pathway analyses—represent the most direct way of translating molecular-level observations into meaningful biological insights. However, significant barriers exist that prevent full utilization of metabolomics and especially lipidomics data in pathway integration. Challenges include the fast turnover and complex interactions of small molecules compared to biological macromolecules, low metabolite annotation rates, isomerism among lipids, and a lack of lipid representation in existing pathway knowledge bases. While these issues stem from a variety of causes, improvements to multiomics pathway integration including better incorporation of lipids into pathway knowledge bases and increased adoption of artificial intelligence approaches can greatly enhance the utility of small molecule -omics data, particularly for lipidomics. Here, we describe the current landscape of multiomics integration tools with an emphasis on support for metabolomics and lipidomics data, we highlight their capabilities and gaps with tangible examples using real multiomics data, and provide our perspective on how these approaches can be improved to better support generation of useful biological insights from complex multiomics data.
- 4 May 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (3)
Open AccessAssessing current capabilities for incorporating lipidomics in multiomics data integration
Comprehensive analyses of multiple biological components including nucleic acids, proteins, metabolites, and lipids (i.e. “multiomics”) provide unique insights into complex biological processes. Combining insights from these components through multiomics data integration enhances the depth and nuance of biological understanding available from these measurements. Among methods that integrate data across different technologies (e.g. mass spectrometry, sequencing), those that link components based on biological prior knowledge—pathway analyses—represent the most direct way of translating molecular-level observations into meaningful biological insights. However, significant barriers exist that prevent full utilization of metabolomics and especially lipidomics data in pathway integration. Challenges include the fast turnover and complex interactions of small molecules compared to biological macromolecules, low metabolite annotation rates, isomerism among lipids, and a lack of lipid representation in existing pathway knowledge bases. While these issues stem from a variety of causes, improvements to multiomics pathway integration including better incorporation of lipids into pathway knowledge bases and increased adoption of artificial intelligence approaches can greatly enhance the utility of small molecule -omics data, particularly for lipidomics. Here, we describe the current landscape of multiomics integration tools with an emphasis on support for metabolomics and lipidomics data, we highlight their capabilities and gaps with tangible examples using real multiomics data, and provide our perspective on how these approaches can be improved to better support generation of useful biological insights from complex multiomics data.
- Open Access
- 4 January 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Assessing current capabilities for incorporating lipidomics in multiomics data integration
Comprehensive analyses of multiple biological components including nucleic acids, proteins, metabolites, and lipids (i.e., “multiomics”) provide unique insights into complex biological processes. Combining insights from these components through multiomics data integration enhances the depth and nuance of biological understanding available from these measurements. Among methods that integrate data across different technologies (e.g. mass spectrometry, sequencing), those that link components based on biological prior knowledge—pathway analyses—represent the most direct way of translating molecular-level observations into meaningful biological insights. However, significant barriers exist that prevent full utilization of metabolomics and especially lipidomics data in pathway integration. Challenges include the fast turnover and complex interactions of small molecules compared to biological macromolecules, low metabolite annotation rates, isomerism among lipids, and a lack of lipid representation in existing pathway knowledge bases. While these issues stem from a variety of causes, improvements to multiomics pathway integration including better incorporation of lipids into pathway knowledge bases and increased adoption of artificial intelligence approaches can greatly enhance the utility of small molecule -omics data, particularly for lipidomics. Here we describe the current landscape of multiomics integration tools with an emphasis on support for metabolomics and lipidomics data, we highlight their capabilities and gaps with tangible examples using real multiomics data, and provide our perspective on how these approaches can be improved to better support generation of useful biological insights from complex multiomics data
- 4 January 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAssessing current capabilities for incorporating lipidomics in multiomics data integration
Comprehensive analyses of multiple biological components including nucleic acids, proteins, metabolites, and lipids (i.e., “multiomics”) provide unique insights into complex biological processes. Combining insights from these components through multiomics data integration enhances the depth and nuance of biological understanding available from these measurements. Among methods that integrate data across different technologies (e.g. mass spectrometry, sequencing), those that link components based on biological prior knowledge—pathway analyses—represent the most direct way of translating molecular-level observations into meaningful biological insights. However, significant barriers exist that prevent full utilization of metabolomics and especially lipidomics data in pathway integration. Challenges include the fast turnover and complex interactions of small molecules compared to biological macromolecules, low metabolite annotation rates, isomerism among lipids, and a lack of lipid representation in existing pathway knowledge bases. While these issues stem from a variety of causes, improvements to multiomics pathway integration including better incorporation of lipids into pathway knowledge bases and increased adoption of artificial intelligence approaches can greatly enhance the utility of small molecule -omics data, particularly for lipidomics. Here we describe the current landscape of multiomics integration tools with an emphasis on support for metabolomics and lipidomics data, we highlight their capabilities and gaps with tangible examples using real multiomics data, and provide our perspective on how these approaches can be improved to better support generation of useful biological insights from complex multiomics data